Focus on earlier identification of heart failure risk
With the U.S. population aging, prevalence of heart failure (HF) is projected to grow by 25% and associated direct costs by 215% by 2030.1
BNP and NT- proBNP: not just for diagnosis and management anymore
The natriuretic peptide (NP) biomarkers, B-type natriuretic peptide (BNP), and N-terminal pro B-type natriuretic peptide (NT-proBNP), which play a role in myocardial stress, have long served as clinically useful markers for heart failure diagnosis and management. New data and guidelines suggest that for patients at risk of developing HF, NP biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing guideline-directed medical therapy, can be useful to prevent the development of new-onset HF.2 This means more people may benefit from BNP and NT-proBNP testing.
HF biomarker testing from Quest Diagnostics3
Which patients warrant extra vigilance for heart failure risk?
Patients who may be at risk for developing heart failure include those with:
- Poorly controlled hypertension
- Known vascular disease
In addition, risk identification may serve as a wake-up call for patients of concern, e.g., those not adhering to medications or otherwise not following their treatment plan.
Trust Quest Diagnostics for your cardiometabolic testing needs
From heart failure testing, to diagnosis and monitoring, our test menu and related services can support you and your patients across the continuum of care.
|Test Name||Test Code||CPT Code(s)*|
|B-Type Natriuretic Peptide (BNP)||37386||83880|
|Cardio IQ® ProBNP, N-terminal||91739||83880|
|Cardio IQ® ST2, Soluble||91823||83006|
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Consider BNP and NT-proBNP testing to help prevent heart failure in your at-risk patients.
|Download the BNP and NT-proBNP brochure|
|Download the Cardio IQ® proBNP, N-terminal test summary|
|Download the Cardio IQ® ST2, Soluble test summary|
|Review test information in our Test Center|
- Konstam MA. Home monitoring should be the central element in an effective program of heart failure disease management. Circulation. 2012;125:820-7.
- Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2017;CIR.0000000000000509. doi: https://doi.org/10.1161/CIR.0000000000000509.
- Adapted from van Kimmenade RRJ and Januzzi JL. Emerging biomarkers in heart failure. Clin Chem. 2012;58(1):127-138.